Effects of Cabergoline on Hyperprolactinemia, Psychopathology, and Sexual Functioning in Schizophrenic Patients

Το τεκμήριο παρέχεται από τον φορέα :
Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών   

Αποθετήριο :
Πέργαμος   

δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*



Effects of Cabergoline on Hyperprolactinemia, Psychopathology, and Sexual Functioning in Schizophrenic Patients

Kalkavoura, Christina S. Michopoulos, Ioannis Arvanitakis, Periklis Theodoropoulou, Pitsa Dimopoulou, Konstantina and Tzebelikos, Errikos Lykouras, Lefteris

scientific_publication_article
Επιστημονική δημοσίευση - Άρθρο Περιοδικού (EL)
Scientific publication - Journal Article (EN)

2013


Antipsychotic medications are associated to different degrees with sexual dysfunction mainly through their potential to induce hyperprolactinemia. Prolactin (PRL) secretion is mainly regulated by the hypothalamic dopaminergic systems. We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL >20 ng/ml for men and PRL > 25 ng/ml for women). In total 80 patients were enrolled; 33 were receiving risperidone, 17 haloperidol, 11 amisulpride, and 8 risperidone microspheres long acting. Based on PRL levels (<50, 50-99, or > 100 ng/ml), patients were assigned in 3 cabergoline doses (0.25, 0.5, and 1 mg/day in 38, 23, and 19 patients, respectively). The psychopathology was evaluated using the Positive and Negative Syndrom Scale (PANSS), and sexual dysfunction was evaluated using the Arizona Sexual Experiences Scale (ASEX). PRL levels were reduced in all patients, from 73.3 (+/- 46.8) to 42.0 (+/- 27.8) at Month 3 and 27.1 (+/- 20.4) at Month 6 (p < .001). ASEX scores declined from 19.1 (+/- 5.1) to 17.6 (+/- 5.5) at Month 3 and 15.0 (+/- 6.5) at Month 6 (p < .001). PANSS scores were reduced in the third and in the sixth month (p = .001 at 6 month vs. baseline). The decrease in PRL was not statistically different between groups. Our data suggest that cabergoline administration to clinically stable patients with schizophrenia may improve sexual functioning without adversely affecting their psychopathologic status, provided that the dose has been suited to the severity of the hyperprolactinemia. (EN)

Αγγλική γλώσσα

Ερευνητικό υλικό ΕΚΠΑ

https://creativecommons.org/licenses/by-nc/4.0/




*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.